76
|
Suda A, Takahashi J, Hao K, Kikuchi Y, Shindo T, Sato K, Sugisawa J, Matsumoto Y, Miyata S, Sakata Y, Shimokawa H. 1345Prognostic impacts of impaired coronary vasodilatation and enhanced coronary vasoconstricting responses in patients with angina and unobstructive coronary arteries. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.1345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
77
|
Kikuchi Y, Takahashi J, Sato K, Sugisawa J, Tsuchiya S, Suda A, Shindo T, Ikeda S, Hao K, Shiroto T, Matsumoto Y, Sakata Y, Shimokawa H. P793Usefulness and safety of fasudil, a selective Rho-kinase inhibitor, for PCI-related myocardial ischemia in interventional cardiology. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
78
|
Tominaga K, Sakata Y, Kusunoki H, Odaka T, Sakurai K, Kawamura O, Nagahara A, Takeuchi T, Fujikawa Y, Oshima T, Kato M, Furuta T, Murakami K, Chiba T, Miwa H, Kinoshita Y, Higuchi K, Kusano M, Iwakiri R, Fujimoto K, Tack JF, Arakawa T. Rikkunshito simultaneously improves dyspepsia correlated with anxiety in patients with functional dyspepsia: A randomized clinical trial (the DREAM study). Neurogastroenterol Motil 2018; 30:e13319. [PMID: 29498457 DOI: 10.1111/nmo.13319] [Citation(s) in RCA: 45] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/11/2017] [Accepted: 01/26/2018] [Indexed: 02/05/2023]
Abstract
BACKGROUND Functional dyspepsia (FD), a heterogeneous disorder, involves multiple pathogenetic mechanisms. Developing treatments for FD has been challenging. We performed a randomized, placebo-controlled, double-blind clinical trial to determine the efficacy of rikkunshito, a Japanese herbal medicine, in FD patients. METHODS FD patients (n = 192) who met the Rome III criteria without Helicobacter pylori infection, predominant heartburn, and depression were enrolled at 56 hospitals in Japan. After 2 weeks of single-blind placebo treatment, 128 patients with continuous symptoms were randomly assigned to 8 weeks of rikkunshito (n = 64) or placebo (n = 61). The primary efficacy endpoint was global assessment of overall treatment efficacy (OTE). The secondary efficacy endpoints were improvements in upper gastrointestinal symptoms evaluated by the Patient Assessment of Upper Gastrointestinal Disorders-Symptom Severity Index (PAGI-SYM), the Global Overall Symptom scale (GOS), and the modified Frequency Scale for the Symptoms of Gastroesophageal Reflux Disease (m-FSSG), and psychological symptoms evaluated by the Hospital Anxiety and Depression Scale (HADS). KEY RESULTS Rikkunshito increased OTE compared to placebo at 8 weeks (P = .019). Rikkunshito improved upper gastrointestinal symptoms (PAGI-SYM, GOS, and m-FSSG) at 8 weeks, especially postprandial fullness/early satiety (P = .015 and P = .001) and bloating (P = .007 and P = .002) of the PAGI-SYM subscales at 4 weeks and 8 weeks. Improvement of HADS at 8 weeks (P = .027) correlated with those of PAGI-SYM (r = .302, P = .001), GOS (r = .186, P = .044), and m-FSSG (r = .462, P < .001), postprandial fullness/early satiety (r = .226, P = .014), dyspepsia (r = .215, P = .019), and PDS (r = .221, P = .016). CONCLUSION & INFERENCES Rikkunshito may be beneficial for FD patients to simultaneously treat gastrointestinal and psychological symptoms.
Collapse
|
79
|
Hatanaka K, Yuki S, Nakano S, Sawada K, Harada K, Okuda H, Ando T, Ogawa K, Furukawa K, Minami S, Saiki T, Ohta T, Kato T, Nakajima J, Sasaki T, Saitoh S, Shindo Y, Tateyama M, Kato S, Nagai H, Sakata Y, Komatsu Y. HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
80
|
Shindo Y, Yuki S, Yagisawa M, Kawamoto Y, Tsuji Y, Hatanaka K, Kobayashi Y, Kajiura S, Ishiguro A, Honda T, Dazai M, Eto K, Nakamura M, Koike M, Ota S, Sato A, Kato K, Ueda A, Fukunaga A, Sekiguchi M, Sakata Y, Komatsu Y. HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of cases of prior regorafenib. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
81
|
Nakamura M, Komatsu Y, Muranaka T, Yagisawa M, Kawamoto Y, Nakatsumi H, Yuki S, Saiki T, Ishiguro A, Tateyama M, Kobayashi Y, Miyagishima T, Takahata T, Sato A, Dazai M, Okuda H, Fujikawa K, Eto K, Muto S, Hatanaka K, Amano T, Sakata Y. HGCSG 1301: A Multicenter, Double-Blind, Randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
82
|
Ishiguro A, Kawamoto Y, Yuki S, Nakano S, Yagisawa M, Sawada K, Muranaka T, Hayashi H, Nakatsumi H, Saiki T, Harada K, Kobayashi Y, Iwanaga I, Hatanaka K, Sakata Y, Komatsu Y. HGCSG 1403: Phase I trial of oxaliplatin/irinotecan/S-1 (OX-IRIS) as first line chemotherapy for unresectable pancreatic cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
83
|
Honda T, Yuki S, Muranaka T, Nakatsumi H, Tsuji Y, Miyagishima T, Yoshida S, Hatanaka K, Sasaki T, Ishiguro A, Muto O, Ohnuma H, Kato S, Sato A, Abe M, Kato K, Onodera K, Eto K, Tateyama M, Amano T, Sakata Y, Komatsu Y. HGCSG1401: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer: Analysis of risk factors for liver dysfunction. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
84
|
Saito S, Toda K, Miyagawa S, Yoshikawa Y, Hata H, Domae K, Matsuura R, Sakata Y, Sawa Y. Hemodynamic Response to Continuous-flow Left Ventricular Assist Device Ramp Test and Volume Loading Predicts Successful Weaning from the Device Support. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
85
|
Tsukamoto Y, Ohtani T, Shiraki T, Ichibori Y, Saito S, Hikoso S, Toda K, Yamaguchi O, Sawa Y, Sakata Y. Baseline and 1-year Follow-up Serial Optical Coherence Tomography Evaluation of Coronary Plaques in Heart Transplant Recipients. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.1067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
86
|
Kawamoto Y, Yuki S, Meguro T, Hatanaka K, Uebayashi M, Iwanaga I, Nakamura M, Eto K, Okuda H, Abe M, Aonuma A, Abe N, Sato A, Nakatsumi H, Muranaka T, Yagisawa M, Oba K, Sakata Y, Sakamoto N, Komatsu Y. HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx660.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
87
|
Yoshita H, Yuki S, Yagisawa M, Tsuji Y, Kobayashi Y, Hatanaka K, Okuda H, Dazai M, Furukawa K, Ogawa K, Minami S, Ishiguro A, Honda T, Ohta T, Eto K, Kato T, Nakajima J, Sasaki T, Sakata Y, Komatsu Y. First report: A retrospective trial for evaluating the safety and efficacy of TAS-102 for patients with metastatic colorectal cancer: HGCSG1503. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx659.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
88
|
Miyagishima T, Yuki S, Muranaka T, Tsuji Y, Ota Y, Hatanaka K, Okuda H, Sasaki T, Dazai M, Konno J, Nakamura M, Ohta T, Honda T, Ishiguro A, Muto O, Kato S, Sato A, Abe M, Sakata Y, Komatsu Y. Analysis of tumor location: A retrospective trial for evaluating the safety and efficacy of regorafenib for patients with metastatic colorectal cancer: HGCSG1401. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx659.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
89
|
Yamasaki M, Kai K, Nomura A, Kono H, Kawakubo H, Sakata Y, Mizuguchi M, Aishima S. Cover Image. Cytopathology 2017. [DOI: 10.1111/cyt.12482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
90
|
Yagisawa M, Nakamura M, Muranaka T, Kawamoto Y, Nakatsumi H, Yuki S, Sasaki T, Meguro T, Dazai M, Ishiguro A, Eto K, Harada K, Kobayashi Y, Miyagishima T, Iwanaga I, Uebayashi M, Hatanaka K, Sakamoto N, Sakata Y, Komatsu Y. Multicenter prospective cohort study to evaluate of eye disorder induced by chemotherapy including S-1 (EyeDropS study/HGCSG1604). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx388.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
91
|
Sakata Y, Iwata H, Ikezawa H, Fudetani R, Tonoda D, Uchida Y, Hasegawa H, Matsuoka T. Prospective observational study of peripheral neuropathy in breast cancer patients treated with eribulin. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
92
|
Yuki S, Komatsu Y, Yagisawa M, Tsuji Y, Harada K, Hatanaka K, Okuda H, Hosokawa A, Ogawa K, Furukawa K, Minami S, Ishiguro A, Honda T, Ohta T, Dazai M, Eto K, Sasaki T, Nakajima J, Sakamoto N, Sakata Y. A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer [HGCSG1503]: Updated analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
93
|
Suda A, Takahashi J, Hao K, Kikuchi Y, Shindo T, Komatsu M, Odaka Y, Matsumoto Y, Miyata S, Sakata Y, Shimokawa H. 1057Important prognostic impact of comorbid coronary microvascular dysfunction in patients with vasospastic angina. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.1057] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
94
|
Tsujinaga S, Iwano H, Murai D, Hayashi T, Yokoyama S, Nishino H, Nakabachi M, Ichikawa A, Abe A, Kawata T, Daimon M, Oonishi T, Sakata Y, Yamada S. P1431Right ventricular strain of a line segment as a feasible parameter of right ventricular systolic function in patients with advanced heart failure referred for left ventricular assist device therapy. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p1431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
95
|
Hao K, Takahashi J, Sakata Y, Miyata S, Shiroto T, Nochioka K, Shimokawa H. 3868Different prognostic impacts of residual coronary stenosis after percutaneous coronary intervention by left ventricular systolic function in patients with ischemic heart failure. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.3868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
96
|
Kasahara S, Sakata Y, Nochioka K, Tsuji K, Abe R, Oikawa T, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. P3384Development of a simple risk score to predict mortality of patients with chronic heart failure with preserved ejection fraction. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p3384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
97
|
Ohyama K, Matsumoto Y, Takanami K, Ota H, Nishimiya K, Sugisawa J, Amamizu H, Uzuka H, Suda A, Shindo T, Kikuchi Y, Hao K, Takahashi J, Sakata Y, Shimokawa H. 1059Evidence for enhanced inflammation of coronary adventitia and perivascular adipose tissue in patients with vasospastic angina - a multi-modality imaging study-. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.1059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
98
|
Yamasaki M, Kai K, Nomura A, Kono H, Kawakubo H, Sakata Y, Mizuguchi M, Aishima S. Colonic poorly differentiated adenocarcinoma with abundant cancer-associated fibroblasts diagnosed by trans-gastric endoscopic ultrasound-guided fine needle aspiration cytology. Cytopathology 2017; 28:442-444. [PMID: 28691754 DOI: 10.1111/cyt.12443] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/03/2017] [Indexed: 02/05/2023]
|
99
|
Tsukamoto Y, Ohtani T, Shiraki T, Ichibori Y, Saito S, Awata M, Toda K, Yamaguchi O, Sawa Y, Sakata Y. Serial Evaluation of Plaque Characteristics in Coronary Artery Lesions Using Optical Coherence Tomography After Heart Transplantation. J Heart Lung Transplant 2017. [DOI: 10.1016/j.healun.2017.01.1453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
100
|
Ioka T, Komatsu Y, Mizuno N, Tsuji A, Ohkawa S, Tanaka M, Iguchi H, Ishiguro A, Kitano M, Satoh T, Yamaguchi T, Takeda K, Kida M, Eguchi K, Ito T, Munakata M, Itoi T, Furuse J, Hamada C, Sakata Y. Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer 2017; 116:464-471. [PMID: 28081543 PMCID: PMC5318973 DOI: 10.1038/bjc.2016.436] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Revised: 10/31/2016] [Accepted: 12/05/2016] [Indexed: 12/18/2022] Open
Abstract
Background: We aimed to compare the efficacy and safety of irinotecan/S-1 (IRIS) therapy with S-1 monotherapy in patients with gemcitabine-refractory pancreatic cancer. Methods: Patients were treated with oral S-1 (80–120 mg for 14 days every 4 weeks) plus intravenous irinotecan (100 mg m−2 on days 1 and 15 every 4 weeks; IRIS group) or oral S-1 group (80–120 mg daily for 28 days every 6 weeks). The primary endpoint was progression-free survival (PFS). Results: Of 137 patients enrolled, 127 were eligible for efficacy. The median PFS in the IRIS group and S-1 monotherapy group were 3.5 and 1.9 months, respectively (hazard ratio (HR)=0.77; 95% confidence interval (CI), 0.53–1.11; P=0.18), while the median overall survival (OS) were 6.8 and 5.8 months, respectively (HR=0.75; 95% CI, 0.51–1.09; P=0.13). Response rate was significantly higher in the IRIS group than in the S-1 monotherapy group (18.3% vs 6.0%, P=0.03). Grade 3 or higher neutropenia and anorexia occurred more frequently in the IRIS group. Conclusions: There was a trend for better PFS and OS in the IRIS group that could be a treatment arm in the clinical trials for gemcitabine-refractory pancreatic cancer.
Collapse
|